English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Tuesday, February 28, 2023
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration
エーザイとバイオジェン、抗アミロイドβプロトフィブリル抗体「レカネマブ」の中国における生物ライセンス申請(BLA)が優先審査に指定
Tuesday, February 21, 2023
Dissolution of Bracco-Eisai Joint Venture
Monday, February 20, 2023
ブラッコ・エーザイの合弁解消について
Monday, January 30, 2023
Lecanemab Receives Priority Review Status in Japan
エーザイとバイオジェン、抗アミロイドβプロトフィブリル抗体「レカネマブ」について、日本において優先審査品目に指定
Friday, January 27, 2023
Eisai: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Accepted by European Medicines Agency
エーザイとバイオジェン、抗アミロイドβプロトフィブリル抗体「レカネマブ」について早期アルツハイマー病に係る販売承認申請が欧州医薬品庁により受理
Thursday, January 19, 2023
Eisai Commences Business Activities at New Pharma Sales Subsidiary in Israel
Eisai Listed as a Global 100 Most Sustainable Corporation for The Seventh Time Highest Ranked Global Pharmaceutical Company

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575